Motor outcomes in patients with infantile and juvenile Pompe disease: Lessons from neurophysiological findings.

[1]  F. Rivier,et al.  Long‐term follow‐up of 64 children with classical infantile‐onset Pompe disease since 2004: A French real‐life observational study , 2023, European journal of neurology.

[2]  B. Neubauer,et al.  Clinical and Genetic Aspects of Juvenile Onset Pompe Disease , 2021, Neuropediatrics.

[3]  D. Rizopoulos,et al.  Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. , 2021, The Lancet. Child & adolescent health.

[4]  A. D. De Groot,et al.  Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease , 2021, Frontiers in Immunology.

[5]  S. Tai,et al.  Airway abnormalities in very early treated infantile‐onset Pompe disease: A large‐scale survey by flexible bronchoscopy , 2020, American journal of medical genetics. Part A.

[6]  M. Kabra,et al.  Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease. , 2019, The Journal of pediatrics.

[7]  Y. Chien,et al.  Clinical features of Pompe disease with motor neuronopathy , 2019, Neuromuscular Disorders.

[8]  D. Rizopoulos,et al.  Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy , 2018, Journal of Inherited Metabolic Disease.

[9]  M. Valsecchi,et al.  Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy , 2018, Orphanet Journal of Rare Diseases.

[10]  R. Giugliani,et al.  Newborn Screening for Pompe Disease , 2017, Pediatrics.

[11]  D. Stockton,et al.  Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. , 2016, JCI insight.

[12]  A. Broomfield,et al.  Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy , 2016, Journal of Inherited Metabolic Disease.

[13]  W. Soong,et al.  Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. , 2016, The Journal of pediatrics.

[14]  Y. Chien,et al.  Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. , 2015, The Journal of pediatrics.

[15]  M. Kroos,et al.  Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease , 2014, Journal of Inherited Metabolic Disease.

[16]  D. de Castro,et al.  Motor function measure: validation of a short form for young children with neuromuscular diseases. , 2013, Archives of physical medicine and rehabilitation.

[17]  D. Güngör,et al.  How to describe the clinical spectrum in Pompe disease? , 2013, American journal of medical genetics. Part A.

[18]  D. Dimmock,et al.  Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease , 2012, Genetics in Medicine.

[19]  B. Byrne,et al.  Pompe disease: design, methodology, and early findings from the Pompe Registry. , 2011, Molecular genetics and metabolism.

[20]  J. E. Wraith,et al.  Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience , 2010, Journal of Inherited Metabolic Disease.

[21]  R. Sidman,et al.  Temporal Neuropathologic and Behavioral Phenotype of 6neo/6neo Pompe Disease Mice , 2008, Journal of neuropathology and experimental neurology.

[22]  Wuh-Liang Hwu,et al.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[23]  R. Desnick,et al.  Enzyme replacement and enhancement therapies for lysosomal diseases , 2004, Journal of Inherited Metabolic Disease.

[24]  P. Kang.  Normal Values Tables , 2017 .

[25]  H. Mandel,et al.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. , 2010, Molecular genetics and metabolism.